Jos van Pelt
Overview
Explore the profile of Jos van Pelt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira I, Torrejon E, Abecasis B, Alexandre B, Gomes R, Verslype C, et al.
SLAS Discov
. 2024 Mar;
29(3):100154.
PMID: 38521503
Sorafenib is a multikinase inhibitor indicated for first-line treatment of unresectable hepatocellular carcinoma. Despite its widespread use in the clinic, the existing knowledge of sorafenib mode-of-action remains incomplete. To build...
2.
Mansour F, Ayadi H, van Pelt J, Elfeki A, Bellassoued K
J Med Food
. 2023 Dec;
27(1):60-71.
PMID: 38150214
Basil ( L.) is distributed worldwide and used in the food, pharmaceutical, and cosmetic industries. Most applications are for the herb basil, recently the basil seeds have also been used...
3.
Mendez-Blanco C, Fondevila F, Fernandez-Palanca P, Garcia-Palomo A, van Pelt J, Verslype C, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067410
In the original publication [...].
4.
van Pelt J, Meeusen B, Derua R, Guffens L, Van Cutsem E, Janssens V, et al.
J Transl Med
. 2023 May;
21(1):317.
PMID: 37170215
Background: Pancreatic ductal adenocarcinoma (PDAC) has a low survival, its incidence is rising and little therapeutic improvements are expected in the near future. It has been observed that Epithelial-to-Mesenchymal transition...
5.
Fondevila F, Mendez-Blanco C, Fernandez-Palanca P, Payo-Serafin T, van Pelt J, Verslype C, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34769197
Early acquisition of sorafenib resistance is responsible for the dismal prognosis of advanced hepatocarcinoma (HCC). Autophagy, a catabolic process involved in liver homeostasis, has been associated with chemosensitivity modulation. Forkhead...
6.
Broadfield L, Duarte J, Schmieder R, Broekaert D, Veys K, Planque M, et al.
Cancer Res
. 2021 Mar;
81(8):1988-2001.
PMID: 33687947
Hepatic fat accumulation is associated with diabetes and hepatocellular carcinoma (HCC). Here, we characterize the metabolic response that high-fat availability elicits in livers before disease development. After a short term...
7.
Bulle A, Dekervel J, Deschuttere L, Nittner D, Van Cutsem E, Verslype C, et al.
Onco Targets Ther
. 2020 Aug;
13:6907-6916.
PMID: 32764982
Purpose: All currently available therapies for the treatment of pancreatic ductal adenocarcinoma (PDAC) show limited success. PDACs fast progression depends on the tumor characteristics and can be influenced by the...
8.
Bulle A, Dekervel J, Deschuttere L, Nittner D, Libbrecht L, Janky R, et al.
Transl Oncol
. 2020 Mar;
13(3):100743.
PMID: 32145636
Background: Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease that can develop therapy resistance over time. The dense stroma in PDAC plays a critical role in tumor progression and...
9.
Galle E, Thienpont B, Cappuyns S, Venken T, Busschaert P, Van Haele M, et al.
Clin Epigenetics
. 2020 Feb;
12(1):27.
PMID: 32059745
Background: Overcoming therapeutic resistance is one of the major hurdles in cancer care. One mechanism contributing to therapeutic resistance is a process in which epithelial cells switch to a mesenchymal...
10.
Mendez-Blanco C, Fondevila F, Fernandez-Palanca P, Garcia-Palomo A, van Pelt J, Verslype C, et al.
Cancers (Basel)
. 2019 Dec;
11(12).
PMID: 31835431
Despite sorafenib effectiveness against advanced hepatocarcinoma (HCC), long-term exposure to antiangiogenic drugs leads to hypoxic microenvironment, a key contributor to chemoresistance acquisition. We aimed to study the role of hypoxia...